fosdenopterin; cyclic pyranopterin monophosphate; cPMP (Nulibry)

Indications

• treatment of molybdenum cofactor deficiency type A

Dosage

• 9.5 mg injection

Adverse effects

• complications related to the intravenous line
• fever, respiratory infections
• vomiting, gastroenteritis & diarrhea
• photosensitivity in animals

Mechanism of action

• replaces missing cyclic pyranopterin monophosphate in individuals with rare genetic disorder

More general terms

• cofactor
• metabolic agent (metabolic modifier)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=135463437
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=145722612